Da	complementarity determining region to partially or fully replace said complementarity
cont	determining region.
	24. The composition of Claim 67 wherein said protein fragment or peptide comprising a T
D	cell receptor antagonist derived from proteolipid protein comprises a peptide analog of [a
14	peptide agonist wherein said peptide agonist is capable of activating a T cell response to
	proteolipid protein.
0	29. The composition of claim 27 wherein said composition comprises a fusion protein in
ν <sub>5</sub>	which said protein fragment or peptide comprising a T cell receptor antagonist derived from
	proteolipid protein is covalently joined to said immunoglobulin or portion thereof.
06	66. A composition comprising an immunoglobulin or a portion thereof linked to a protein
	fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an
	Fc receptor and said protein fragment or peptide comprises a [known] T cell receptor antagonist
	derived from proteolipid protein, sand composition having the property of being endocytosed by
	cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist
	in association with endogenous MHC Class II molecules.
	68. The composition of Claim 66, wherein said protein fragment or peptide comprising [the
V7	T cell receptor antagonist] a T cell receptor antagonist derived from proteolipid protein is
	covalently linked to said immuroglobulin or portion thereof.
De	69. The composition of Claim 68, wherein said protein fragment or peptide comprising a T
12	cell receptor antagonist derived from proteolipid protein comprises a peptide analog of [a
	peptide agonist wherein said peptide agonist is capable of activating a T cell response to]
	proteolipid protein.
Û9	72. The composition of Claim 67, wherein the composition comprises a fusion protein in
	which said protein fragment or peptide comprising [said T cell receptor antagonist] comprising
	a T cell receptor antagonist derived from proteolipid protein is covalently joined to said
	immunoglobulin or portion thereof.
Dio	73. The composition of Claim 72, wherein said protein fragment or peptide comprising [said
	T cell receptor antagonist] a T cell receptor antagonist derived from proteolipid protein is
	positioned within at least one complementary determining region to partially or fully replace said

08/779,767 January 7, 1997

Appl. No. Filed

complementarity determining region.